A more detailed systematic review focused on 16 adjuvant randomized trials using LHRH agonists in 9,022 patients with hormone receptor-positive (HR+) BC (91.8% were ER+ and the remainder were ER−PgR+) [26]. The gene discussed is GNRH1; the disease is breast cancer.